GALECTIN-3 AND NT-proBNP AS BIOMARKERS OF HEART FAILURE DECOMPENSATION

Aim. To compare the levels of galectin-3 and N-terminal brain natriuretic peptide precursor (NT-proBNP) in heart failure patients with saved ejection fraction of the left ventricle (HF-sEF) and heart failure with low ejection fraction (HF-lEF). To study the possibilities for implementation of galect...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu. V. Dubolazova, O. M. Drapkina
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2017-02-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/829
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849249941087584256
author Yu. V. Dubolazova
O. M. Drapkina
author_facet Yu. V. Dubolazova
O. M. Drapkina
author_sort Yu. V. Dubolazova
collection DOAJ
description Aim. To compare the levels of galectin-3 and N-terminal brain natriuretic peptide precursor (NT-proBNP) in heart failure patients with saved ejection fraction of the left ventricle (HF-sEF) and heart failure with low ejection fraction (HF-lEF). To study the possibilities for implementation of galectin-3 and NT-proBNP as markers of HF decompensation in HF-sEFMaterial and methods. Totally, 30 patients with HF-sEF included (17 females, 13 males, mean age 65±8 y.o.) and 30 patients with HF-lEF (11 females, 19 males, mean age 63±11 y.o.). All patients underwent physical examination, 6-minute walking test, clinical condition assessment by clinical condition score (CCS), echocardiography (Echo), tissue doppler imaging, measurement of galectin-3 and NT-proBNP levels at admission.Results. The difference of mean levels of NT-proBNP in HF-sEF and HF-lEF did not differ significantly (153,23±114,44 fM/ml and 142,45±90,82 fM/ml, resp., t=0,4, p=0,68). A direct correlation was found for HF clinics in both groups (r=0,46, p<0,05, 95% CI). In HF-sEF the negative correlation was found for the mean level of NT-proBNP and 6-minute walking test results by CCS, direct correlation between clinical condition of patients by CCS (r=0,048, p=0,02, 95% CI), direct correlation of clinical presentation and real systolic pressure in in pulmonary artery (r=0,4, p=0,03, 95% CI); negative correlation of the mean NT-proBNP and peak A velocity (r=-0,52, p=0,003, 95% CI). Mean level of galectin-3 in blood plasma in HF-sEF (0,98±1,93 hg/mL) is significantly higher than in HF-lEF (0,13±0,07 ng/mL) (t=2,41, p=0,01). There was no relation found for the main clinical presentation of HF and galectin-3 level in HF patients. In both groups there was no relation between the mean galectin-3 level and 6-minute test, and clinical condition by CCS. There was positive relation of ejection fraction of the left ventricle by Echo and mean level of galectin-3 (r=0,45, p=0,012, 95% CI).Conclusion. The level of NT-proBNP does not differ in HF-sEF and HF-lEF patients and is related to the severity of CHF. Therefore, NT-proBNP might be used as a marker of CHF decompensation. Level of galecton-3 is significantly higher in HFsEF patients and does not relate on severity of CHF. Both markers can be used for diagnostics of CHF patients and to reveal HF-sEF before Echo is done.
format Article
id doaj-art-50127664bd054cfd897f0ce0c749ea39
institution Kabale University
issn 1560-4071
2618-7620
language Russian
publishDate 2017-02-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj-art-50127664bd054cfd897f0ce0c749ea392025-08-20T03:57:26Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202017-02-01019510110.15829/1560-4071-2017-1-95-101783GALECTIN-3 AND NT-proBNP AS BIOMARKERS OF HEART FAILURE DECOMPENSATIONYu. V. Dubolazova0O. M. Drapkina1National Research Center for Preventive Medicine of the Ministry of HealthNational Research Center for Preventive Medicine of the Ministry of HealthAim. To compare the levels of galectin-3 and N-terminal brain natriuretic peptide precursor (NT-proBNP) in heart failure patients with saved ejection fraction of the left ventricle (HF-sEF) and heart failure with low ejection fraction (HF-lEF). To study the possibilities for implementation of galectin-3 and NT-proBNP as markers of HF decompensation in HF-sEFMaterial and methods. Totally, 30 patients with HF-sEF included (17 females, 13 males, mean age 65±8 y.o.) and 30 patients with HF-lEF (11 females, 19 males, mean age 63±11 y.o.). All patients underwent physical examination, 6-minute walking test, clinical condition assessment by clinical condition score (CCS), echocardiography (Echo), tissue doppler imaging, measurement of galectin-3 and NT-proBNP levels at admission.Results. The difference of mean levels of NT-proBNP in HF-sEF and HF-lEF did not differ significantly (153,23±114,44 fM/ml and 142,45±90,82 fM/ml, resp., t=0,4, p=0,68). A direct correlation was found for HF clinics in both groups (r=0,46, p<0,05, 95% CI). In HF-sEF the negative correlation was found for the mean level of NT-proBNP and 6-minute walking test results by CCS, direct correlation between clinical condition of patients by CCS (r=0,048, p=0,02, 95% CI), direct correlation of clinical presentation and real systolic pressure in in pulmonary artery (r=0,4, p=0,03, 95% CI); negative correlation of the mean NT-proBNP and peak A velocity (r=-0,52, p=0,003, 95% CI). Mean level of galectin-3 in blood plasma in HF-sEF (0,98±1,93 hg/mL) is significantly higher than in HF-lEF (0,13±0,07 ng/mL) (t=2,41, p=0,01). There was no relation found for the main clinical presentation of HF and galectin-3 level in HF patients. In both groups there was no relation between the mean galectin-3 level and 6-minute test, and clinical condition by CCS. There was positive relation of ejection fraction of the left ventricle by Echo and mean level of galectin-3 (r=0,45, p=0,012, 95% CI).Conclusion. The level of NT-proBNP does not differ in HF-sEF and HF-lEF patients and is related to the severity of CHF. Therefore, NT-proBNP might be used as a marker of CHF decompensation. Level of galecton-3 is significantly higher in HFsEF patients and does not relate on severity of CHF. Both markers can be used for diagnostics of CHF patients and to reveal HF-sEF before Echo is done.https://russjcardiol.elpub.ru/jour/article/view/829heart failure with normal ejection fractionnt-probnpgalectin-3biomarkers of heart failure
spellingShingle Yu. V. Dubolazova
O. M. Drapkina
GALECTIN-3 AND NT-proBNP AS BIOMARKERS OF HEART FAILURE DECOMPENSATION
Российский кардиологический журнал
heart failure with normal ejection fraction
nt-probnp
galectin-3
biomarkers of heart failure
title GALECTIN-3 AND NT-proBNP AS BIOMARKERS OF HEART FAILURE DECOMPENSATION
title_full GALECTIN-3 AND NT-proBNP AS BIOMARKERS OF HEART FAILURE DECOMPENSATION
title_fullStr GALECTIN-3 AND NT-proBNP AS BIOMARKERS OF HEART FAILURE DECOMPENSATION
title_full_unstemmed GALECTIN-3 AND NT-proBNP AS BIOMARKERS OF HEART FAILURE DECOMPENSATION
title_short GALECTIN-3 AND NT-proBNP AS BIOMARKERS OF HEART FAILURE DECOMPENSATION
title_sort galectin 3 and nt probnp as biomarkers of heart failure decompensation
topic heart failure with normal ejection fraction
nt-probnp
galectin-3
biomarkers of heart failure
url https://russjcardiol.elpub.ru/jour/article/view/829
work_keys_str_mv AT yuvdubolazova galectin3andntprobnpasbiomarkersofheartfailuredecompensation
AT omdrapkina galectin3andntprobnpasbiomarkersofheartfailuredecompensation